Trading Report: The Regeneron Pharmaceuticals Inc. (REGN) Earns “Buy” Rating from Roth Capital

The Regeneron Pharmaceuticals Inc. (REGN) Earns “Buy” Rating from Roth Capital

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)‘s stock had its “buy” rating reissued by equities research analysts at Roth Capital in a research report issued on Wednesday. They currently have a $520.00 price objective on the biopharmaceutical company’s stock. Roth Capital’s price target would suggest a potential upside of 34.70% from the company’s current price.

A number of other equities analysts have also recently commented on the stock. RBC Capital Markets reaffirmed an “outperform” rating and set a $648.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, October 4th. Robert W. Baird reaffirmed a “neutral” rating and set a $448.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, October 4th. Zacks Investment Research cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 4th. Leerink Swann set a $530.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, October 3rd. Finally, Canaccord Genuity reaffirmed a “hold” rating and set a $450.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Friday, September 30th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $480.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 3.20% during midday trading on Wednesday, reaching $373.71. 498,424 shares of the company’s stock traded hands. The stock has a 50-day moving average of $400.58 and a 200 day moving average of $392.25. The company has a market cap of $39.10 billion, a P/E ratio of 58.30 and a beta of 1.31. Regeneron Pharmaceuticals has a 52-week low of $329.09 and a 52-week high of $592.59.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported $2.82 EPS for the quarter, topping the Zacks’ consensus estimate of $2.65 by $0.17. Regeneron Pharmaceuticals had a net margin of 15.65% and a return on equity of 23.77%. The firm earned $1.21 billion during the quarter, compared to analysts’ expectations of $1.24 billion. During the same period in the previous year, the business posted $2.89 earnings per share. The company’s revenue for the quarter was up 21.4% compared to the same quarter last year. On average, analysts anticipate that Regeneron Pharmaceuticals will post $11.02 earnings per share for the current fiscal year.

In related news, Director Joseph L. Goldstein sold 2,125 shares of the stock in a transaction on Friday, July 29th. The stock was sold at an average price of $425.00, for a total value of $903,125.00. Following the completion of the sale, the director now directly owns 15,125 shares of the company’s stock, valued at approximately $6,428,125. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 10.40% of the stock is owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in REGN. Raymond James Trust N.A. bought a new stake in Regeneron Pharmaceuticals during the third quarter worth approximately $278,000. Jacobs & Co. CA bought a new stake in Regeneron Pharmaceuticals during the third quarter worth approximately $345,000. Fisher Asset Management LLC raised its stake in Regeneron Pharmaceuticals by 1.1% in the third quarter. Fisher Asset Management LLC now owns 620 shares of the biopharmaceutical company’s stock worth $249,000 after buying an additional 7 shares during the last quarter. Harding Loevner LP raised its stake in Regeneron Pharmaceuticals by 91.7% in the third quarter. Harding Loevner LP now owns 318,565 shares of the biopharmaceutical company’s stock worth $128,070,000 after buying an additional 152,425 shares during the last quarter. Finally, Advisory Services Network LLC raised its stake in Regeneron Pharmaceuticals by 80.7% in the third quarter. Advisory Services Network LLC now owns 600 shares of the biopharmaceutical company’s stock worth $241,000 after buying an additional 268 shares during the last quarter. 68.16% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Related posts

Leave a Comment